Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.

Article Details

Citation

Ilies MA, Vullo D, Pastorek J, Scozzafava A, Ilies M, Caproiu MT, Pastorekova S, Supuran CT

Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.

J Med Chem. 2003 May 22;46(11):2187-96.

PubMed ID
12747790 [ View in PubMed
]
Abstract

Two series of halogenated sulfonamides have been prepared. The first consists of mono/dihalogenated sulfanilamides, whereas the second one consists of the mono/dihalogenated aminobenzolamides, incorporating equal or different halogens (F, Cl, Br, and I). These sulfonamides have been synthesized from the corresponding anilines by acetylation (protection of the amino group), chlorosulfonylation, followed either by amidation, or reaction with 5-amino-1,3,4-thiadiazole-2-sulfonamide (and eventually deacetylation). All these compounds, together with the six clinically used sulfonamide inhibitors (acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, and brinzolamide) were investigated as inhibitors of the transmembrane, tumor-associated isozyme carbonic anhydrase (CA) IX. Inhibition data against the classical, physiologically relevant isozymes I, II, and IV were also obtained. CA IX shows an inhibition profile which is generally completely different from those of isozymes I, II, and IV, with potent inhibitors (inhibition constants in the range of 12-40 nM) among both simple aromatic (such as 3-fluoro-5-chloro-4-aminobenzenesulfonamide) as well as heterocyclic compounds (such as acetazolamide, methazolamide, 5-amino-1,3,4-thiadiazole-2-sulfonamide, aminobenzolamide, and dihalogenated aminobenzolamides). This first detailed CA IX inhibition study revealed many interesting leads, suggesting the possibility to design even more potent and eventually CA IX-selective inhibitors, with putative applications as antitumor agents.

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
5-{[(4-AMINO-3-CHLORO-5-FLUOROPHENYL)SULFONYL]AMINO}-1,3,4-THIADIAZOLE-2-SULFONAMIDECarbonic anhydrase 2Ki (nM)0.37.522Details
AcetazolamideCarbonic anhydrase 1Ki (nM)2507.522Details
AcetazolamideCarbonic anhydrase 2Ki (nM)127.522Details
BrinzolamideCarbonic anhydrase 2Ki (nM)37.522Details
DiclofenamideCarbonic anhydrase 1Ki (nM)12007.522Details
DiclofenamideCarbonic anhydrase 2Ki (nM)387.522Details
DorzolamideCarbonic anhydrase 1Ki (nM)500007.522Details
DorzolamideCarbonic anhydrase 2Ki (nM)97.522Details
EthoxzolamideCarbonic anhydrase 1Ki (nM)257.522Details
EthoxzolamideCarbonic anhydrase 2Ki (nM)87.522Details
MethazolamideCarbonic anhydrase 1Ki (nM)507.522Details
MethazolamideCarbonic anhydrase 2Ki (nM)147.522Details